After publication of this article \[[@pone.0213092.ref001]\], concerns were raised about image irregularities in [Fig 2C](#pone.0213092.g001){ref-type="fig"}, specifically that the Non CF Beclin-1 panel and the CF Beclin-1 panel appear to be taken from the same image. The authors acknowledge that an error was made in generating [Fig 2C](#pone.0213092.g001){ref-type="fig"} of this article. In [Fig 2C](#pone.0213092.g001){ref-type="fig"}, the Western blot image of Beclin-1 non-CF was inadvertently shown for both the CF and non-CF lanes. We have corrected this error and the updated [Fig 2C](#pone.0213092.g001){ref-type="fig"} shows the correct Beclin-1 blots for both CF and non-CF from the original experiments at the original exposure. The corrected Beclin-1 blot does not change the original conclusions for this figure. Please see the correct [Fig 2](#pone.0213092.g001){ref-type="fig"} here.

![IFN-γ increases *B*. *cenocepacia* co-localization with p62 and decreases p62 accumulation in CF.\
2A) Confocal microscopy for non-CF and CF macrophages infected with m-RFP expressing k56-2. IFN-y or rapamycin treatment was administered after 1 hour of infection for a 24 hour treatment period. p62 is stained green, and macrophage nuclei are stained blue with DAPI. Co-localization of bacteria with p62 is noted in yellow in the bottom panel. 2B) The percentage of bacterial co-localization with p62 was scored for over 100 macrophages per condition, n  =  5 subjects per condition, Mann-Whitney testing. 2C) Immunoblot for non-CF and CF macrophages demonstrating p62 accumulation in CF with reduction during IFN-y therapy, representative of 5 subjects. Immunoblot of beclin-1 levels for non-CF and CF macrophages from cell lysates of control (NT) and MDMs infected with k56-2+/− treatment with IFN-γ, n  =  4.](pone.0213092.g001){#pone.0213092.g001}

Additionally, we have provided a new Supporting Information file, [S1 File](#pone.0213092.s001){ref-type="supplementary-material"}, showing one of the other representative independent Western blots to support the CF data in [Fig 2C](#pone.0213092.g001){ref-type="fig"}. With this Correction, the authors also provide the original raw data for [Fig 2C](#pone.0213092.g001){ref-type="fig"} (in [S2](#pone.0213092.s002){ref-type="supplementary-material"}--[S4](#pone.0213092.s004){ref-type="supplementary-material"} Files), as well as the original data for [Fig 2A and 2B](#pone.0213092.g001){ref-type="fig"} (in [S5](#pone.0213092.s005){ref-type="supplementary-material"} and [S6](#pone.0213092.s006){ref-type="supplementary-material"} Files). All proteins were normalized to their loading controls. Please view Supporting Information files [S1](#pone.0213092.s001){ref-type="supplementary-material"}--[S6](#pone.0213092.s006){ref-type="supplementary-material"} Files below.

A member of *PLOS ONE*'s Editorial Board confirmed that the new results support the results and conclusions of the published article.

The authors apologize for the error in the published article.

Supporting information {#sec001}
======================

###### Supporting experiment for [Fig 2C](#pone.0213092.g001){ref-type="fig"}.

Representative immunoblot of replicate data for [Fig 2C](#pone.0213092.g001){ref-type="fig"}. Immunoblot for non-CF and CF macrophages demonstrating p62 accumulation in CF with reduction during IFN-y therapy. Immunoblot of beclin-1 levels for non-CF and CF macrophages from cell lysates of control (NT) and MDMs infected with k56-2+/− treatment with IFN-γ, with no change during treatment.

(TIF)

###### 

Click here for additional data file.

###### [Fig 2](#pone.0213092.g001){ref-type="fig"} original beclin-1 immunoblots.

Original beclin-1 immunoblots for independent experiments used in [Fig 2C](#pone.0213092.g001){ref-type="fig"}. Immunoblot of beclin-1 levels for non-CF and CF macrophages from cell lysates of control (NT) and MDMs infected with k56-2+/− treatment with IFN-γ. Other experimental conditions not presented in the manuscript are also present.

(TIF)

###### 

Click here for additional data file.

###### [Fig 2](#pone.0213092.g001){ref-type="fig"} original p62 immunoblots.

Original p62 immunoblots for independent experiments used in [Fig 2C](#pone.0213092.g001){ref-type="fig"}. Immunoblot for non-CF and CF macrophages demonstrating p62 accumulation in CF with reduction during IFN-y therapy. Other experimental conditions not presented in the manuscript are also present.

(TIF)

###### 

Click here for additional data file.

###### [Fig 2](#pone.0213092.g001){ref-type="fig"} original loading controls.

Original loading control immunoblots for independent experiments used in [Fig 2C](#pone.0213092.g001){ref-type="fig"}. Other experimental conditions not presented in the manuscript are also present.

(TIF)

###### 

Click here for additional data file.

###### [Fig 2A](#pone.0213092.g001){ref-type="fig"} images.

Original images of fluorescent channels used for [Fig 2A](#pone.0213092.g001){ref-type="fig"}. Each condition has an overlay, DAPI, infection denoted with RFP-expressing bacteria, and p62 detected by GFP-antibody.

(ZIP)

###### 

Click here for additional data file.

###### [Fig 2B](#pone.0213092.g001){ref-type="fig"} raw data.

Raw data used to create [Fig 2B](#pone.0213092.g001){ref-type="fig"}. Percent co-localization of bacteria with p62 per 100 macrophages are shown for each condition. Raw data was used in GraphPad Prism to create [Fig 2B](#pone.0213092.g001){ref-type="fig"}.

(XLSX)

###### 

Click here for additional data file.
